About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA-approved prescription drugs for dermatological conditions. The Journey Medical team comprises industry experts with extensive exp ...

CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (NASDAQ: MRCC) today announced its financial results for the first quarter ended March 31, 2025. Except where the context suggests otherwise, the terms "Company," "we," "us," and "our" refer to Monroe Capital Corporation (together with its subsidiaries). First Quarter 2025 Financial Highlights Chief Executive Officer Theodore L. Koenig commented, "We are pleased to announce that we paid a $0.25 per share dividend during the first quarter r ...

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs. Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today annou ...

MOUNTAIN VIEW, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- LegalZoom.com, Inc. (Nasdaq: LZ) today announced results for its first quarter ended March 31, 2025. "Our first quarter results reflect accelerating subscription growth and solid progress towards our goal of double- digit subscription revenue growth in the fourth quarter," said Jeff Stibel, Chairman and Chief Executive Officer of LegalZoom. "While no company is immune to today's volatile environment, our first quarter results exceeded our expectations ...

First Quarter 2025 Revenues of $302.6 Million Reflect 9.2 Percent Growth and 7.4 Percent Organic Growth Over First Quarter 2024 Revenues of $277.2 Million First Quarter 2025 Consolidated Book to Bill Ratio of 1.2 to 1 and Bookings of $365.6 Million Last Twelve Months Ended March 30, 2025 Consolidated Book to Bill Ratio of 1.2 to 1 and Bookings of $1.401 Billion SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National ...

Alex Braun abraun@acumenpharm.com NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. Media: AcumenPR@westwicke.com The live webc ...

By comparison, in the second quarter of fiscal year 2024, Symbotic had revenue of $393 million, a net loss of $55 million and adjusted EBITDA of $9 million. Cash and cash equivalents increased by $52 million from the prior quarter to $955 million at the end of the second quarter of fiscal year 2025. "Our execution has improved, and our margins expanded," said Symbotic Chairman and Chief Executive Officer Rick Cohen. "With stronger project execution and a compelling roadmap of product innovation, we remain w ...

About Photronics BROOKFIELD, Conn., May 07, 2025 (GLOBE NEWSWIRE) -- Photronics, Inc. (Nasdaq:PLAB), a worldwide leader in photomask technologies and solutions, announced today its participation in the following upcoming financial conferences: Date: Thursday, May 29 Event: TD Cowen's 53 Annual Technology, Media & Telecom Conference Location: New York, NY Presentation Time: 10:15 a.m. ET Date: Tuesday, June 10 Event: D.A. Davidson's 1 Annual Technology & Consumer Conference Location: Nashville, TN Date: Wedn ...

Corporate Highlights and Recent Developments Expanded Pipeline with INB-600 Gamma-Delta T Cell Engager Platform Demonstrated Additional Clinical Progress Across Gamma-Delta T Cell Therapy Pipeline NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the first quarter ended March 31, 2025 and recent corporate highlights. "IN8bio stands ...

Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics' produ ...